Source comparison
Tesamorelin + Ipamorelin Blend: Clinical Comparison
Visceral Fat Reduction (26 weeks, CT-measured) 15.2% vs baseline 8.1% vs baseline 18.7% vs baseline Synergistic. The blend produces greater fat loss than either peptide's individual contribution would predict GH Pulse Amplitude (relative to baseline) 1.8× incr
This comparison does not assign a generated winner or score.
- Visceral Fat Reduction (26 weeks, CT-measured)
- 15.2% vs baseline
- 8.1% vs baseline
- 18.7% vs baseline
- Synergistic. The blend produces greater fat loss than either peptide's individual contribution would predict
- GH Pulse Amplitude (relative to baseline)
- 1.8× increase
- 1.4× increase
- 2.4× increase
- The combination amplifies pulse strength without extending duration. Preserving physiological pulsatility
- Insulin Sensitivity (M-value, clamp study)
- +18% improvement
- +11% improvement
- +23% improvement
- Dual-pathway activation (GH-mediated + AMPK-mediated) produces additive insulin-sensitizing effects
- Lean Mass Preservation During Deficit
- +1.2kg over 12 weeks
- +0.6kg over 12 weeks
- +1.8kg over 12 weeks
- GH's anabolic effects on muscle are preserved while ipamorelin prevents ghrelin-driven catabolism
- Cortisol Elevation (% change from baseline)
- +3% (not significant)
- 0% (no change)
- +2% (not significant)
- Ipamorelin's selective ghrelin agonism avoids the cortisol spikes seen with non-selective secretagogues
- Documented Adverse Events (nausea, injection site reactions)
- 12% of participants
- 8% of participants
- 14% of participants
- Mild and transient. Most resolve within 2–3 weeks of continued use